December 06, 2016

ESC/EAS Task Force provides practical guidance for PCSK9 inhibitors; who to target, LDL-thresholds, future insights

In a new Commentary, our Scientific Editor Jane Stock highlights the practical guidance – who to target, LDL-thresholds and future insights – given on PCSK9 inhibitors in the recent European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement.

"The availability of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, for use in the clinic has highlighted the need for practical guidance. In response, this Joint Task Force of the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) has provided a document to aid clinicians in the appropriate use of these novel treatments. In balancing the clinical need for these treatments with their cost, the Task Force has not surprisingly taken a conservative approach, especially given the lack of clinical outcomes evidence to date..."

Read the full Commentary >>

Young Investigator Awards for outstanding publications - nominations open!

These annual EAS prizes for young scientists are intended to recognize distinction shown by publications that contribute to the advancement of knowledge in the field of atherosclerosis and linked metabolic disturbances.

Each recipient will receive a prize of € 2000 and will be invited to make a short presentation of their work at the annual EAS Congress. The winners of the Awards for outstanding publications 2016 will be invited to present at EAS 2017 Prague.

Nominations open now until February 01, 2017.

Read more and nominate a candidate >>

EAS 2017, Prague:

Make sure your EAS membership 2016 is up to date - register for reduced fee at the congress!

The participants at EAS annual Congress are world leaders in atherosclerosis research and clinical practice, and the Congress lends itself to networking and interaction. We particularly welcome EAS members to attend, and Society members benefit from reduced Congress registration fee, with savings of up to 100 € compared to non-member fees.

Members should pay full Individual membership subscription before December 31, 2016 to qualify for member-rate registration fee at Congress 2017 – there’s still time to become a member before the end of the year.

Read more about the EAS membership and how to apply >>

Register to EAS 2017 Prague >>


Find out more

About EAS

EAS Membership

EAS Congress

EAS Educational Initiatives

EAS Publications

European Lipoprotein Club (ELC)

EAS-FH Studies Collaboration (FHSC)

Visit: eas-society.org

About this email

You have received this email because you are currently subscribed to receive general correspondence from EAS.

  

European Atherosclerosis Society
Mässans Gata 18
Box 5243
SE-402 24, Gothenburg SWEDEN

Organisation number: 802418-0427

This email was sent to '@@email@@' from European Atherosclerosis Society.
If you wish to stop receiving email from us, you can simply remove yourself by visiting: @@unsubscribe_url@@

 

European Atherosclerosis Society © 2016